Literature DB >> 21114565

Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis.

Lucas Schirmer1, Jack P Antel, Wolfgang Brück, Christine Stadelmann.   

Abstract

Neuroaxonal damage and loss are increasingly recognized as disability determining features in multiple sclerosis (MS) pathology. However, little is known about the long-term sequelae of inflammatory demyelination on neurons and axons. Spinal cord tissue of 31 MS patients was compared to three amyotrophic lateral sclerosis (ALS) and 10 control subjects. MS lesions were staged according to the density of KiM-1P positive macrophages and microglia and the presence of myelin basic protein (MBP) positive phagocytes. T cells were quantified in the parenchyma and meninges. Neuroaxonal changes were studied by immunoreactivity (IR) for amyloid precursor protein (APP) and variably phosphorylated neurofilaments (SMI312, SMI31, SMI32). Little T cell infiltration was still evident in chronic inactive lesions. The loss of SMI32 IR in ventral horn neurons correlated with MS lesion development and disease progression. Similarly, axonal loss in white matter (WM) lesions correlated with disease duration. A selective reduction of axonal phosphorylated neurofilaments (SMI31) was observed in WM lesions. In ALS, the loss of neuronal SMI32 IR was even more pronounced, whereas the relative axonal reduction resembled that found in MS. Progressive neuroaxonal neurofilament alterations in the context of chronic inflammatory demyelination may reflect changes in neuroaxonal metabolism and result in chronic neuroaxonal dysfunction as a putative substrate of clinical progression.
© 2011 The Authors; Brain Pathology © 2011 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21114565     DOI: 10.1111/j.1750-3639.2010.00466.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  34 in total

1.  Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein.

Authors:  Elodie Brison; Hélène Jacomy; Marc Desforges; Pierre J Talbot
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

3.  Visualization of the Breakdown of the Axonal Transport Machinery: a Comparative Ultrastructural and Immunohistochemical Approach.

Authors:  Sebastian Rühling; Franziska Kramer; Selina Schmutz; Sandra Amor; Zhan Jiangshan; Christoph Schmitz; Markus Kipp; Tanja Hochstrasser
Journal:  Mol Neurobiol       Date:  2018-09-21       Impact factor: 5.590

Review 4.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

5.  Diffusion tensor MRI as a biomarker in axonal and myelin damage.

Authors:  Wint Yan Aung; Soe Mar; Tammie Ls Benzinger
Journal:  Imaging Med       Date:  2013-10-01

Review 6.  Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.

Authors:  Vaibhav Singh; Ajai Tripathi; Ranjan Dutta
Journal:  Proteomics       Date:  2019-06-21       Impact factor: 3.984

7.  HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Authors:  Patrick J Gannon; Cagla Akay-Espinoza; Alan C Yee; Lisa A Briand; Michelle A Erickson; Benjamin B Gelman; Yan Gao; Norman J Haughey; M Christine Zink; Janice E Clements; Nicholas S Kim; Gabriel Van De Walle; Brigid K Jensen; Robert Vassar; R Christopher Pierce; Alexander J Gill; Dennis L Kolson; J Alan Diehl; Joseph L Mankowski; Kelly L Jordan-Sciutto
Journal:  Am J Pathol       Date:  2017-01       Impact factor: 4.307

8.  MRI characteristics and scoring in HDLS due to CSF1R gene mutations.

Authors:  Christina Sundal; Jay A Van Gerpen; Alexandra M Nicholson; Christian Wider; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Anne Borjesson-Hanson; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Shinsuke Fujioka; Michael G Heckman; Ryan J Uitti; Keith A Josephs; Matt Baker; Oluf Andersen; Rosa Rademakers; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

9.  Towards programming immune tolerance through geometric manipulation of phosphatidylserine.

Authors:  Reid A Roberts; Timothy K Eitas; James D Byrne; Brandon M Johnson; Patrick J Short; Karen P McKinnon; Shannon Reisdorf; J Christopher Luft; Joseph M DeSimone; Jenny P Ting
Journal:  Biomaterials       Date:  2015-08-20       Impact factor: 12.479

10.  Myelin loss does not lead to axonal degeneration in a long-lived model of chronic demyelination.

Authors:  Chelsey M Smith; Elizabeth Cooksey; Ian D Duncan
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.